Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study

Fung, Scott; Kwan, Peter; Fabri, Milotka; Horban, Andrzej; Pelemis, Mijomir; Hann, Hie-Won; GÜREL, SELİM; Caruntu, Florin; Flaherty, John; Massetto, Benedetta; Kim, Kyungpil; Kitrinos, Kathryn; Subramanian, G.; McHutchison, John; Yee, Leland; Elkhashab, Magdy; Berg, Thomas; Sporea, Loan; Yurdaydin, Cihan; Husa, Petr; Jablkowski, Maciej; Gane, Edward

doi:10.1016/j.jhep.2016.08.008

Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study

Copy For Citation

Fung S., Kwan P., Fabri M., Horban A., Pelemis M., Hann H., ...More

JOURNAL OF HEPATOLOGY, vol.66, no.1, pp.11-18, 2017 (SCI-Expanded)

Publication Type: Article / Article
Volume: 66 Issue: 1
Publication Date: 2017
Doi Number: 10.1016/j.jhep.2016.08.008
Journal Name: JOURNAL OF HEPATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.11-18
Keywords: Tenofovir disoproxil fumarate, Emtricitabine, Lamivudine resistant, Viral suppression, Bone mineral density, Renal function, LONG-TERM EFFICACY, VIRUS INFECTION, COMBINATION THERAPY, ADEFOVIR, ENTECAVIR, SAFETY, MONOTHERAPY, CIRRHOSIS, LEVEL, RISK
Bursa Uludag University Affiliated: Yes

Abstract

Background & Aims: Long-term treatment with tenofovir disoproxil fumarate (TDF) alone, or in combination with emtricitabine (FTC) is associated with sustained viral suppression in patients with lamivudine resistant (LAM-R) chronic hepatitis B (CHB).